HC Wainwright Decreases Earnings Estimates for Urogen Pharma

Urogen Pharma (NASDAQ:URGN) – Analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Urogen Pharma in a research note issued on Monday, June 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.80) per share for the quarter, down from their previous estimate of ($0.74). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.43 EPS.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analysts’ expectations of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%.

A number of other equities analysts have also recently commented on the company. LADENBURG THALM/SH SH started coverage on Urogen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the stock a “neutral” rating in a report on Friday, June 13th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Urogen Pharma in a report on Thursday, June 12th. Scotiabank reissued an “outperform” rating on shares of Urogen Pharma in a report on Friday, June 13th. Finally, Guggenheim reissued a “buy” rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $32.86.

Urogen Pharma Stock Performance

Shares of URGN opened at $14.87 on Wednesday. The business’s fifty day simple moving average is $8.79 and its two-hundred day simple moving average is $10.10. The company has a current ratio of 5.65, a quick ratio of 5.47 and a debt-to-equity ratio of 4.77. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $18.15. The company has a market cap of $685.66 million, a price-to-earnings ratio of -4.68 and a beta of 0.40.

Insiders Place Their Bets

In other news, insider Mark Schoenberg sold 5,162 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the transaction, the insider now owns 153,378 shares of the company’s stock, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of URGN. Jane Street Group LLC boosted its holdings in shares of Urogen Pharma by 94.3% in the first quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after purchasing an additional 24,839 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Urogen Pharma by 216.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock valued at $48,227,000 after purchasing an additional 2,983,368 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Urogen Pharma by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company’s stock valued at $4,348,000 after purchasing an additional 23,292 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in Urogen Pharma by 347.5% during the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock worth $1,262,000 after buying an additional 88,577 shares during the period. Institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.